IMMX News and Press, Immix Biopharma Inc.

LOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host i...

2026-02-09 06:04:20 ET Graig Suvannavejh from Mizuho Securities issued a price target of $14.00 for IMMX on 2026-02-09 10:35:04. The adjusted price target was set to $14.00. At the time of the announcement, IMMX was trading at $6.74. The overall price target consensus is...

2026-01-28 12:30:25 ET Immix Biopharma ( NASDAQ: IMMX ) recently secured a strategic regulatory win that has significantly altered the company's investment profile. The company announced that the FDA granted Breakthrough Therapy Designation to its lead candidate, NXC-201 . This desi...

– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting – – Final data expected this year followed by planned BLA submission – LOS...

2025-12-11 00:10:07 ET Intro A couple of years since my initiation piece, Immix Biopharma ( IMMX ), the only company advancing a one-time therapy in AL amyloidosis ((ALA)), a rare but deadly protein-aggregating disease similar to multiple myeloma ((MM)), is reach...

– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX ...

2025-12-08 01:27:15 ET Immix Biopharma ( IMMX ) has priced an underwritten offering structured to generate $100 million in gross proceeds, that consists of 19,117,646 shares of common stock at $5.10 per share and pre-funded warrants for 490,196 shares at $5.09 per warrant......

LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten reg...

– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee – – In four out of five pending patients, MRD negativity in bone marrow predicts future complete response, potentially increasing future CR rate t...

2025-11-12 08:59:00 ET More on Immix Biopharma Immix Biopharma: I Am Surprised To Reaffirm A 'Buy' Seeking Alpha’s Quant Rating on Immix Biopharma, Inc. Historical earnings data for Immix Biopharma, Inc. Financial information for Immix Biopharma, Inc. ...